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Abstract
Background: Typically observed at 2 y after surgical resection, late recurrence is a major challenge in the management of
hepatocellular carcinoma (HCC). We aimed to develop a genomic predictor that can identify patients at high risk for late
recurrence and assess its clinical implications.
Methods and Findings: Systematic analysis of gene expression data fromhuman liver undergoing hepatic injury and regeneration
revealed a 233-gene signature that was significantly associated with late recurrence of HCC. Using this signature, we developed a
prognostic predictor that can identify patients at high risk of late recurrence, and tested and validated the robustness of the
predictor in patients (n=396) who underwent surgery between 1990 and 2011 at four centers (210 recurrences during a median of
3.7 y of follow-up). In multivariate analysis, this signature was the strongest risk factor for late recurrence (hazard ratio, 2.2; 95%
confidence interval, 1.3–3.7; p=0.002). In contrast, our previously developed tumor-derived 65-gene risk score was significantly
associated with early recurrence (p=0.005) but not with late recurrence (p=0.7). In multivariate analysis, the 65-gene risk score was
the strongest risk factor for very early recurrence (,1 y after surgical resection) (hazard ratio, 1.7; 95% confidence interval, 1.1–2.6;
p=0.01). The potential significance of STAT3 activation in late recurrence was predicted by gene network analysis and validated
later. We also developed and validated 4- and 20-gene predictors from the full 233-gene predictor. The main limitation of the study
is that most of the patients in our study were hepatitis B virus–positive. Further investigations are needed to test our prediction
models in patients with different etiologies of HCC, such as hepatitis C virus.
Conclusions: Two independently developed predictors reflected well the differences between early and late recurrence of
HCC at the molecular level and provided new biomarkers for risk stratification.
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Introduction
Liver cancer is the second-leading cause of cancer mortality
worldwide, accounting for approximately 600,000 cancer-related
deaths annually [1]. The incidence rate of hepatocellular
carcinoma (HCC), the most common type of liver cancer, has
increased in the United States recently and is expected to double
in the next 10 to 20 y [2–4]. Despite recent advances in diagnosis
and management, the median survival of patients with HCC is less
than 8 mo, and the disease is still one of the most fatal cancers [4].
Surgical resection, liver transplantation, and local ablation remain
the only curative modalities of HCC [5,6], and recurrence occurs
in up to 70% of patients within 5 y after resection [7,8]. Therefore,
among patients who have received curative treatment, survival is
jeopardized by tumor recurrence.
In HCC, two distinct types of recurrence are known. Early
recurrence arises from primary cancer cells disseminating to the
surrounding liver and is usually observed within the first 2 y after
surgery. In contrast, late recurrence, which is typically observed
.2 y after surgery, appears to be a result of chronic liver damage
known as the ‘‘field effect,’’ and produces de novo tumors that are
independent of resected primary tumors [7]. The two types of
recurrence have different clinical courses and probably appear in
distinct biological contexts [9]. For better disease management, it
is therefore important to uncover the biological characteristics of
each type of recurrence and to develop distinct molecular
prognostication systems that can identify patients at high risk for
either type. Despite the importance of managing recurrence, our
knowledge of the genetic alterations associated with either type,
especially late recurrence, is fragmentary.
Chronic injury and inflammation are known to promote tumor
development. HCC is one of the best known examples, as more
than 90% of HCCs arise in the context of hepatic injury and
inflammation [10–12]. Chronically unresolved inflammation is
frequently associated with persistent hepatic injury and concurrent
regeneration, which prime the liver for development of HCC [13].
This process is highly similar to a persistent wound-healing
response, regardless of the differences among various etiological
factors such as viruses, alcohol, and fatty liver [14,15]. Therefore,
we hypothesized that gene expression patterns significantly
associated with hepatic injury and regeneration (HIR) would
reflect the potential risk of HCC development as well as the de
novo recurrence of HCC, and that these patterns could serve as
predictive markers to identify patients with high risk of de novo
recurrence after treatment.
We and other researchers have discovered several genomic
predictors for recurrence of HCC [16–23]. In particular, one study
identified a prognostic gene expression signature (the Broad
signature) that was significantly associated with late recurrence of
HCC in a patient population that was mostly hepatitis C virus
(HCV)–positive [20]. However, it is currently unknown whether
this signature is applicable to HCC associated with other
etiological factors. Furthermore, molecular or genomic predictors
that can predict and discriminate early and late recurrence have
not been firmly established. In the current study, we aimed to
analyze gene expression data from human livers undergoing liver
injury with regeneration in order to develop a genomic predictor
for late recurrence of HCC that is associated with hepatitis B virus
(HBV) and a new prognostication model for prediction and
discrimination of early and late recurrence of HCC after surgery.
Methods
Study Design: Patients and Cohorts
This is a retrospective multi-center cohort study aimed at
investigating the association of a gene expression signature
reflecting HIR in human liver with recurrence of HCC and
developing a genomic predictor that can identify patients with a
high risk of recurrence after surgical treatment. Archived tissue
samples (tumors and matched surrounding non-tumor tissues) of
72 HCC patients (cohort 1) undergoing hepatectomy as primary
treatment at the Dongsan Medical Center of Keimyung Univer-
sity, Daegu, Korea, and the Guro Hospital of Korea University
College of Medicine, Seoul, Korea, between 26 December 2001
and 3 June 2011 were included in this study. Patients were
consecutively enrolled and selected on the basis of the availability
of both tumor tissues and non-tumor surrounding tissues. All liver
tissues were frozen in liquid nitrogen and stored at 280uC until
RNA extraction. The study protocols were approved by the
Institutional Review Boards at Dongsan Medical Center, Guro
Hospital, and the University of Texas MD Anderson Cancer
Center, and all participants provided written informed consent.
Patients in cohort 1 were followed up prospectively at least once
every 3 mo after surgery. Recurrence-free survival, which was
defined as the time from surgery to the first confirmed recurrence,
was censored when a patient died or was alive without recurrence
at last contact. To test the robustness of the genomic predictor,
gene expression data from two independent cohorts were used.
Gene expression and clinical data from Queen Mary Hospital of
University of Hong Kong (cohort 2, n= 96) and Fudan University
in China (cohort 3, n= 228) were obtained from Gene Expression
Omnibus (GSE22058 and GSE14520, respectively) [24,25].
Patients in the two validation cohorts underwent surgery between
1990 and 2007. The baseline characteristics of all three cohorts are
shown in Table 1. The patients in the three cohorts are largely
representative of those with HBV.
Gene Expression Data from Human Tissues
To identify a gene expression signature that faithfully reflects
HIR in human liver, i.e., a HIR signature, we acquired gene
expression data from liver biopsies of liver transplantation and
hepatectomy patients from the National Center for Biotechnology
Information’s Gene Expression Omnibus database. The first and
second sets of biopsies were taken from the livers of deceased
donors (n= 13) and living donors (n= 8), respectively (GSE12720)
[26]. The first core biopsies were taken before manipulation of the
liver, and the second biopsies were taken after reperfusion
following completion of bile duct anastomosis. A third set of
biopsies was taken before and after surgery from remnant liver of
patients who had undergone partial hepatectomy as treatment for
colon cancer metastasis or hepatoblastoma (n= 4, GSE15239).
Gene expression data from cohort 1 were generated using the
Illumina microarray platform HumanHT-12 version 4. Briefly,
total RNA was extracted from fresh-frozen tissues using a mirVana
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RNA isolation and labeling kit (Ambion). For each sample, 500 ng
of total RNA was used for labeling and hybridization according to
the manufacturer’s protocols. After the bead chips were scanned
with an Illumina BeadArray Reader, the microarray data were
normalized using the quantile normalization method in the Linear
Models for Microarray Data package in the R language
environment [27]. The expression level of each gene was
transformed into log2 base before further analysis. Primary
microarray data from human liver tissues are available in the
National Center for Biotechnology Information’s Gene Expression
Omnibus public database (accession number GSE39791).
Selection of Genes in the Hepatic Injury and
Regeneration Signature
We identified genes that were differentially expressed between two
series of biopsies in three different datasets (partial hepatectomy,
deceased-donor liver transplantation, and living-donor liver trans-
plantation). Genes were considered statistically significant if their p-
value was less than 0.005. This stringent significance threshold was
used to limit the number of false-positive findings. We also performed
a global test of whether the expression profiles differed between two
classes (two series of biopsies) by permuting the labels of which arrays
corresponded to which classes. For each permutation, the p-values
were recomputed, and the number of genes significant at the 0.005
level was noted. The proportion of the permutations that gave at least
as many significant genes as the actual data was the significance level
of the global test. A total of 325 gene features (representing 233
unique genes) were identified as the HIR signature.
Statistical Analysis
We used BRB ArrayTools for analysis of gene expression data
[28]. Genes differentially expressed between the two classes of
HCC were identified using a random-variance t-test [29].
Expression was considered statistically significant if the p-value
was less than 0.005. To stratify HCC patients as being at low risk
or high risk of de novo late recurrence of disease according to the
HIR signature, we applied a classification algorithm based on a
Bayesian compound covariate predictor (see Text S1) [30].
For patient stratification in our cohorts according to the 186-
gene Broad surrounding tissue signature, we applied a weighted
gene approach to stratify HCC patients as described in a previous
study [20]. Out of the 186 genes, 170 were present in the
microarray platforms from three cohorts. Gene expression data
were centralized independently across all samples before they were
integrated. The patients were stratified into two risk groups using a
Cox score derived in a previous study [20]. Briefly, each gene was
weighted using the corresponding Cox score, and all patients were
ranked by the summation of gene weights. In the Broad risk score,
a higher score is associated with poorer prognosis. The patients
whose gene weights were higher than the lowest gene weight of the
poor prognosis group in the Broad cohort were classified as the
poor prognosis group; those patients whose gene weights were
lower than the highest gene weights of the good prognosis group in
the Broad cohort were classified in the good prognosis group.
Prediction analysis of microarrays (PAM) was carried out as
described previously [31]. In addition to PAM, multivariate
logistic regression analysis was carried out to find minimum genes
in the prediction model. Briefly, univariate analysis was first
applied to genes in the HIR signature to identify genes whose
expression was significantly associated with recurrence-free
survival in the pooled patient cohort (p,0.005), yielding 13 genes.
Next, backward stepwise multivariable regression analysis was
carried out to find genes as independent predictors of recurrence
(p,0.1). Four genes (RALGDS, IER3, CEBPD, and SLC2A3)
were identified from the analysis.
Patient prognoses were estimated using Kaplan–Meier plots and
the log-rank test. We used multivariate Cox proportional hazards
regression analysis to evaluate independent prognostic factors
associated with recurrence-free survival. Recurrence-free survival
was defined as the time from surgery to the first confirmed
recurrence; data were censored when a patient died or was alive
without recurrence at last contact. As covariates we used sex, age,
alpha-fetoprotein concentration, infection with HBV, liver cirrhosis,
tumor size, tumor number, vascular invasion, Barcelona Clinic Liver
Cancer (BCLC) tumor stage, 65-gene risk score, and the HIR
signature [32]. All statistical tests were two-tailed. A p,0.05 indicated
Table 1. Baseline characteristics of HCC patients.
Variable Cohort 1 (n =72) Cohort 2 (n=96) Cohort 3 (n =228)
Male sex 58 (80.6%) 78 (81.3%) 201 (88.2%)
Median (range) age (years) 57.5 (29–77) 55 (27–80) 50 (21–77)
AFP .300 ng/ml 18 (25.0%) 36 (37.5%) 104 (45.6%)
HBV 60 (83.3%) 84 (87.5%) 209 (91.7%)
Liver cirrhosis 36 (50.0%) 60 (62.5%) 211 (92.5%)
Tumor size #5 cm 45 (62.5%) 36 (37.5%) 145 (63.6%)
Single tumor 60 (83.3%) 71 (74.0%) 183 (80.3%)
Vascular invasion 24 (33.3%) 47 (49.0%) 88 (38.6%)
BCLC stage*
0 5 (6.9%) 4 (4.2%) 20 (8.8%)
A 53 (73.6%) 64 (66.7%) 144 (63.2%)
B 8 (11.1%) 19 (19.8%) 22 (9.6%)
C 6 (8.3%) 9 (9.4%) 26 (11.4%)
Median follow-up (months) 33.1 45.7 51.9
*BCLC stage was not available for 16 patients of cohort 3.
AFP, alpha-fetoprotein.
doi:10.1371/journal.pmed.1001770.t001
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Figure 1. Hepatic injury and regeneration gene expression signature from human liver. (A) Venn diagram of human genes whose
expression levels are significantly different before and after liver transplantation or partial hepatectomy. Three gene lists (X, Y, and Z) represent
differentially expressed genes from three datasets (partial hepatectomy [PHx], deceased-donor transplantation [DD], and living-donor transplantation
[LD]). A p-value of,0.005 was required for a gene to be retained. (B) Expression patterns of the 325 probes representing 233 unique genes shared by
the three patient groups. The data are presented in matrix format, in which rows represent individual genes, and columns represent each tissue
sample. Each cell in the matrix represents the expression level of a gene feature in an individual tissue sample. The colors red and green in cells reflect
relatively high and low expression levels, respectively, as indicated in the scale bar (log2 transformed scale). Colored bars at the top of the heat map
represent samples as indicated.
doi:10.1371/journal.pmed.1001770.g001
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statistical significance. All statistical analyses were conducted in the R
language environment (http://www.r-project.org).
Gene Network Analysis for Identification of Dominant
Transcription Factors
We used the gene network analysis built into Ingenuity Pathway
Analysis to identify potential upstream transcription factors that
regulate gene expression patterns enriched in the HIR subtype.
The analysis is based on prior knowledge of expected effects of
transcriptional factors on their target genes stored in the Ingenuity
Knowledge Base [33]. Briefly, the analysis examines the known
targets of each transcription factor in the HIR signature and
compares their direction of change (i.e., expression in the HIR
subtype relative to the quiescent [QT] subtype) to what is expected
from the literature. If the direction of change is consistent with the
literature across the majority of targets, then the transcriptional
factor is predicted to be active in the HIR subtype, whereas if the
direction of change is mostly inconsistent (anti-correlated) with the
literature, then the transcriptional factor is predicted to be inactive
in the HIR subtype. If there is no clear pattern, then there is no
prediction either way. Regulation z-score was used to estimate the
activation state of the transcription factors. An absolute z-score of
.2 was considered significant as suggested by Ingenuity Pathway
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Figure 2. Construction of prediction models in test cohorts. (A) A schematic overview of the strategy used for constructing prediction models
and evaluating predicted outcomes based on the 325-gene HIR signature. (B–D) Kaplan–Meier plots of the HIR and QT subgroups predicted by the
Bayesian compound covariate predictor in cohorts 1 (B), 2 (C), and 3 (D). p-Values were obtained by log-rank test. The vertical lines indicate censored
data. BCCP, Bayesian compound covariate predictor; LOOCV, leave-one-out cross-validation; RFS, recurrence-free survival.
doi:10.1371/journal.pmed.1001770.g002
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Figure 3. Kaplan–Meier survival plots of recurrence free survival of patients from pooled cohorts. Patients were stratified by the HIR
signature (A) or the 65-gene risk score (B). All patients (n= 396) are plotted in the left panel, patients with #2 y of follow-up (early recurrence) in the
middle panel, and patients with more than 2 y of follow-up (late recurrence) in the right panel. p-Values were obtained from the log-rank test. The
vertical lines denote observations that were censored owing to loss to follow-up or on the date of the last contact. RFS, recurrence-free survival.
doi:10.1371/journal.pmed.1001770.g003
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Analysis. The overlap p-values generated by Fisher’s exact test
were used to estimate the statistical significance of overlap between
the dataset genes and the genes regulated by a transcription factor.
Immunohistochemistry
Surrounding liver tissues from 20 patients with HCC (ten with
early recurrence [#2 y] and ten with late recurrence [.2 y]) were
investigated for immunohistostaining validation. For comparison,
normal liver tissues obtained from nine donors for liver
transplantation were used as normal control. Representative
sections of formalin-fixed, paraffin-embedded tissues were used
for immunohistochemistry. Primary antibodies against STAT3
(Clone 124H6, Cell Signaling Technology; dilution 1:2,000) and
p-STAT3 (Tyr705; Clone D3A7, Cell Signaling Technology;
dilution 1:200) were used. Briefly, 4-mm-thick sections of the tissues
were deparaffinized and rehydrated. After treatment with a 3%
hydrogen peroxide solution for 10 min to block endogenous
peroxidases, the sections were pretreated in 10 mM citrate buffer
(pH 6.0) in a microwave oven for 15 min for antigen retrieval.
After incubation with the primary antibodies, the sections were
processed using the EnVision detection system (Dako) according to
the manufacturer’s instructions, and 3,39-diaminobenzidine tetra-
hydrochloride was used as a chromogen. All sections were
counterstained with Mayer hematoxylin. For interpretation of
the immunohistochemical stain results, the staining intensities of
STAT3 were graded on a scale of 0 to 2 (0, negative; 1, moderately
positive; 2, strongly positive), and the extent of distribution was
rated on a scale of 0 to 3 (0, positive in ,1%; 1, 1%–30%; 2,
31%–70%; 3, 71%–100%). For p-STAT3, the staining intensities
were graded on a scale of 0 to 3 (0, negative; 1, weakly positive; 2,
moderately positive; 3, strongly positive), and the extent of
distribution was also rated on a scale of 0 to 3 (0, not positive;
1, 0.1%–1%; 2, 1%–5%; 3,.6%). The histoscore was determined
by multiplying the intensity scores by the distribution scores
(histoscore for STAT3: score 0, 0; score 1, 1–3; score 2, 4–6;
histoscore for p-STAT3: score 0, 0–1; score 1, 2–4; score 2, 6–9).
Quantitative Reverse Transcription PCR Experiments
The mRNA expression levels of 19 genes (BIRC3, GADD45B,
IL1RN, LDLR, MCL1, RALGDS, CDKN1A, CCL20, ADM,
MYC, DUSP5, BCL3, SOD2, SERPINE1, PHLDA1,
C13ORF15, IER3, CEBPD, and SLC2A3) were quantified using
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) experiments. Total RNAs from the surrounding
non-tumor liver tissues of 24 patients in cohort 1 were reverse-
transcribed using a first-strand cDNA synthesis kit (Promega,
according to the manufacturer’s specifications). The resulting
cDNAs were assayed using OriGene primers specific to each gene
Table 2. Univariate and multivariate Cox regression analyses of recurrence-free survival of patients in two different recurrence
groups.
Characteristics Univariate Analysis
Multivariate Analysis with 65-
Gene RS
Multivariate Analysis with
HIR Signature
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
Very early recurrence group (,1 y, n=125*)
Patient sex (male or female) 1.1 (0.6–1.9) 0.84
Age (.60 y or #60 y) 0.9 (0.6–1.3) 0.47
AFP (.300 ng/ml or #300 ng/ml) 1.2 (0.8–1.7) 0.40
Cirrhosis (yes or no) 1.2 (0.7–1.9) 0.48
Tumor size (.5 cm or #5 cm) 1.6 (1.2–2.4) 0.01 1.2 (0.7–1.9) 0.34
Multinodular tumors (yes or no) 1.4 (0.9–2.2) 0.13
Microvessel invasion (yes or no) 2.0 (1.3–2.9) ,0.001 1.6 (1.0–2.5) 0.03
BCLC stage (0/A or B/C) 1.9 (1.3–2.9) 0.001 1.3 (0.8–2.1) 0.25
HIR signature# (HIR or QT) 1.0 (0.7–1.5) 0.97
65-gene RS# (high or low) 1.8 (1.2–2.8) 0.003 1.8 (1.2–2.7) 0.008
Late recurrence group (.2 y, n=215*)
Patient sex (male or female) 1.6 (0.7–3.4) 0.26
Age (.60 y or #60 y) 1.0 (0.6–1.7) 0.97
AFP (.300 ng/ml or #300 ng/ml) 0.7 (0.4–1.2) 0.78
Cirrhosis (yes or no) 0.9 (0.5–1.6) 0.72
Tumor size (.5 cm or #5 cm) 1.2 (0.7–2.1) 0.45
Multinodular tumors (yes or no) 1.1 (0.6–2.3) 0.73
Microvessel invasion (yes or no) 1.5 (0.9–2.5) 0.11
BCLC stage (0/A or B/C) 1.8 (0.9–3.5) 0.08 1.7 (0.9–3.4) 0.11
HIR signature# (HIR or QT) 2.2 (1.3–3.8) 0.002 2.2 (1.3–3.7) 0.002
65-gene RS# (high or low) 1.1 (0.6–2.1) 0.73
*Patients without BCLC stage were not included in multivariate analysis.
#Two subgroups of the prognostic signatures were used as covariates during analysis.
AFP, alpha-fetoprotein; RS, risk score.
doi:10.1371/journal.pmed.1001770.t002
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and the Mastercycler ep realplex system (Eppendorf). Cycling
conditions were 95uC for 30 s, followed by 40 cycles of 95uC for
5 s, 62uC for 30 s, and 72uC for 20 s. Relative amounts of mRNAs
were calculated from the threshold cycle number using expression
levels of GAPDH as an endogenous control. All experiments were
performed in triplicate, and average values are presented.
Results
The Hepatic Injury and Regeneration Signature and Its
Association with Recurrence of HCC
Because injury-mediated wound healing triggers hepatic regenera-
tion and inflammation that can prime the liver for development of
HCC [13], we tried to find genes whose expression patterns are highly
associated with injury and regeneration in human liver. To do this, we
used gene expression data from three types of injured livers: livers from
patients with partial hepatectomy, livers from deceased-donor liver
transplantations, and livers from living-donor liver transplantations.
We first independently selected genes whose expression patterns
differed significantly (p,0.005) before and after hepatic injury with
regeneration in the three data-sets. The expression of 325 probes
representing 233 unique genes (the HIR signature) was significantly
altered in all three datasets (Figure 1; Table S1).
Because the expression patterns of selected genes should reflect
persistent HIR, mimicking the priming condition for HCC
development, we hypothesized that the HIR signature would be
highly associated with the development of HCC or de novo
recurrence of HCC. Thus, we applied the HIR classification
algorithm to gene expression data from patients’ surrounding non-
tumor liver tissues to test whether it could predict the recurrence of
HCC after surgery. Gene expression data of surrounding tissues
from the 72 patients in cohort 1 were used for this analysis, and the
Bayesian compound covariate predictor algorithm [30] was
applied (Figure 2A) as described in Text S1.
When patients in cohort 1 were dichotomized according to the
HIR signature, 23 patients (32%) were predicted to have a high
probability (.0.5) of having the HIR signature (HIR subgroup),
and 49 patients (68%), a high probability of having the QT
signature (QT subgroup). Recurrence-free survival differed signif-
icantly by subgroup (p=0.01 by log-rank test; Figure 2B), strongly
indicating that the HIR signature can identify patients with a high
risk of overall recurrence after surgery.
We further tested the association of the HIR signature with
recurrence in the independent cohort 2 by applying the HIR
classification algorithm to gene expression data from surrounding
tissues and found that recurrence-free survival between the
predicted subgroups differed significantly (p=0.02; Figure 2C).
The robustness of the signature’s association with patient
prognosis was further validated in another, larger independent
cohort (p=0.004 in cohort 3; Figure 2D). The results from these
three independent HCC cohorts clearly demonstrate a strong
association between the HIR signature and HCC recurrence.
Prediction of Late Recurrence of HCC by HIR Signature
Because de novo recurrence largely comprises late recurrence,
which usually occurs .2 y after surgery [7], we carried out a
subset analysis of the pooled data to assess the ability of the HIR
signature to predict early and late recurrence. The signature
lacked a significant association with early recurrence (recurrence
#2 y after surgery; p=0.2), but was significantly associated with
late recurrence (recurrence .2 y after surgery; p=0.001;
Figure 3A). Furthermore, when we carried out stepwise subset
analysis for recurrence more than 2 y, 3 y, and 4 y after surgery,
the significance of the association of the HIR signature with late
recurrence remained the same (Figure S1), providing evidence of a
strong association between the HIR signature and late recurrence
regardless of the cutoff time for late recurrence. This finding
strengthens our hypothesis of a direct correlation of the HIR
signature with de novo development of HCC.
Prediction of Early Recurrence of HCC by a Tumor-
Derived 65-Gene Risk Score
Using gene expression data from tumors, we had previously
developed a 65-gene risk score that can identify patients at high
risk for HCC recurrence after surgery [34]. When we applied it to
gene expression data from tumors of the same patients (n= 396),
the risk score was significantly associated with a high overall
recurrence rate (p=0.009; Figure 3B). However, it was signifi-
cantly associated with early recurrence only (p=0.005) and failed
to identify patients at high risk for late recurrence (p=0.7),
suggesting that this tumor-derived signature is more directly
correlated with recurrence mediated by intrahepatic metastasis of
primary tumors, which usually occurs within 2 y after surgery [7].
Because recurrence is the leading cause of death among HCC
patients during the first year after surgery [35–37], we further
divided early recurrence patients into very early (,1 y) and
intermediate (between 1 and 2 y) recurrence subpopulations and
assessed the ability of two different predictors, the tumor-derived
65-gene risk score and the HIR signature, to prognosticate each of
the recurrence types. As we expected, the HIR signature was not
significantly associated with very early (p=0.7) or intermediate
recurrence (p=0.3) but remained significantly associated with late
recurrence (p=0.001) (Figure S2). The tumor-derived risk score
was significantly associated with the very early recurrence group
(p,0.001) but not with the intermediate recurrence group (p=0.4)
or the late recurrence group (p=0.7) (Figure S2). The fact the both
signatures failed to identify patients at high risk for recurrence
between 1 and 2 y after surgical resection suggests that
intermediate recurrence might be a mixture of metastatic and de
novo recurrence.
Clinical Significance of the Prognostic Genomic
Signatures
We next assessed the prognostic association between the two
predictors (the HIR signature and the 65-gene risk score) and
known demographic and clinical risk factors. For the very early
recurrence subgroup (recurrence less than 1 y after surgical
resection), significant predictors of recurrence-free survival were
the 65-gene risk score (p=0.003) and BCLC stage (p=0.001),
which is the most frequently used clinical staging system and
already a well-known risk factor for HCC recurrence (Table 2) [5].
When the 65-gene risk score was included in the multivariate
model, it was the strongest predictor of recurrence-free survival
(hazard ratio, 1.8; 95% confidence interval, 1.2–2.7; p=0.008).
The HIR signature was not a significant predictor of very early
recurrence.
In the late recurrence subgroup (recurrence more than 2 y after
surgical resection), the HIR signature (p=0.002) and BCLC stage
(p=0.08) were important predictors of recurrence-free survival
(Table 2). The HIR signature was the stronger predictor in
multivariate analysis (hazard ratio, 2.2; 95% confidence interval,
1.3–3.7; p=0.002). The 65-gene risk score was not a significant
predictor of late recurrence.
Because the BCLC staging system recommends curative
modalities, such as surgery, for only selected patients with HCC
(i.e., BCLC stage 0 and A), we then limited our analysis to patients
whose tumors were BCLC stage 0 or A at the time of surgery
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Figure 4. Kaplan–Meier survival plots of recurrence free survival of patients with HCC stratified by the Broad signature. (A) All
patients (n= 396) are plotted in the left panel, those with early recurrence (#2 y) in the middle panel, and those with late recurrence (.2 y) in the
right panel. (B) Patients were stratified into three groups by integrating outcomes from two prognostic models (HIR and Broad signatures); (1) HIR
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doi:10.1371/journal.pmed.1001770.g004
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(n=290). The significant association between the HIR signature
and late recurrence remained the same regardless of the cutoff
time for late recurrence (Figure S3). Likewise, the association of
the 65-gene risk score with early recurrence remained significant
(Figure S4).
We next examined the concordance of the HIR signature with a
previously developed 186-gene prognostic signature predicting late
recurrence called the Broad signature [20]. When the Broad
classification algorithm was applied to our cohort, 93 patients were
classified into the high-risk group for late recurrence. Consistent
with a previous report [20], patients in the Broad high-risk group
had significantly worse recurrence-free survival rates (both overall
and for late recurrence) (Figure 4A). The outcomes of the two
independent prognostic models showed moderate concordance: of
the 136 patients in the HIR subgroup, 54 were identified as being
at high risk by the Broad signature (r=0.27 by Cramer V statistics;
p,0.001) (Table S2). It is also interesting that only four genes
overlapped in both prognostic signatures, suggesting that the two
signatures may capture different biological characteristics associ-
ated with late recurrence of HCC. This notion was supported by
the improved prognostication when the outcomes of both
prognostic models were integrated (Figure 4B). Furthermore, the
hazard ratio for late recurrence in the high-risk group was
substantially increased in the integrated model regardless of the
cutoff for defining late recurrence (Table 3).
Biological Insights of Early and Late Recurrence
Signatures
To gain better insight into the molecular characteristics of the
HIR signature, we categorized genes according to their known
functions based on the Ingenuity Knowledge Base repository [33].
As we expected, many genes associated with the inflammatory
response, inflammatory disease, and cell death were significantly
enriched in the signature (Table S3), suggesting that the HIR
signature reflects well the tissue damage that occurs during liver
transplantation and hepatectomy. Other significantly enriched
categories were cellular growth and proliferation, cancer, cell
cycle, and cellular movement, which suggests that the signature
also reflects the initiation of regeneration. In line with previous
observations indicating a close association of HIR with the
development and progression of HCC [38–42], many functional
categories of genes in the signature are closely related to cancer
development. We next carried out gene network analysis of the
233 genes in the HIR signature to uncover potential upstream
regulators of the HIR signature, and discovered strong over-
representation of five transcription factors, NOTCH1, STAT3,
PDX1, TP53, and RELA (Table S4). Functional connectivity of
the gene network further identified potential interaction between
NOTCH1 and STAT3 (Figure 5A). This observation is in good
agreement with the well-known role of STAT3 in liver regener-
ation and the potential interaction between the STAT3 and
NOTCH pathways [43–45].
We also assessed genes whose expression in surrounding non-
tumor liver tissues from patients in all three cohorts was
significantly different between the HIR and QT subgroups (p,
0.001 by two-sample t-test) and identified 177 genes (Figure S5).
We then examined the activation status of transcription factors in
the HIR subgroup. STAT3 (p,0.001) and NOTCH1 (p,0.001)
were again significantly activated in the HIR subgroup (Figure S6),
strongly supporting the idea that these transcription factors and
the signaling pathways associated with them play key roles in late
de novo recurrence of HCC. To further validate the activation of
STAT3 in surrounding non-tumor tissues in HCC with late
recurrence, we carried out immunohistostaining of STAT3 and p-
STAT3, an indicator of STAT3 activation [46], with normal liver
tissue, surrounding tissues of HCC with early recurrence (,1 y),
and surrounding tissues of HCC with late recurrence (.3 y).
Activation of STAT3 was significantly higher in surrounding
tissues of HCC with late recurrence than in surrounding tissues of
HCC with early recurrence or in normal liver tissue (Figure 5B–
5D; Table S5). In addition, we also remeasured expression of
downstream targets of NOTCH1 (MYC, BIRC3, CDKN1A,
CEBPD, and SERPINE1) in surrounding tissues using qRT-
PCR methods. Consistent with our prediction, expression of
downstream targets was significantly higher in HIR subtype than
QT subtype samples (Figure S7), suggesting that transcriptional
activity of NOTCH1 might be more active in HIR subtype. Taken
together, these data strongly support our prediction based on gene
network analysis.
We next carried out similar analysis with the 65 genes of the risk
score associated with early recurrence. Unlike the HIR signature,
the vast majority of the genes in the risk score were in functional
categories related to angiogenesis and invasion (Table S6),
supporting the notion that early recurrence is largely mediated
by intrahepatic metastasis. Taken together, these results strongly
suggest that the 65-gene risk score and the HIR signature reflect
well the biological characteristics or mechanisms that are
accountable for two distinct types of HCC recurrence, and that
they can be used to identify patients at risk for early or late
recurrence, respectively.
Minimum Number of Genes for a Prognostic Model
Because the number of genes in the HIR signature (233 genes) is
too large for easy translation of current findings into clinical
practice, we estimated the minimum number of genes that can
faithfully predict the HIR and QT subgroups. When the PAM
algorithm that can find subsets of genes that best characterize each
class [31] was applied to the HIR signature, ten to 20 genes were
estimated to be sufficient to construct reliable prediction models
with a 10% miscalculation rate (Figure S8). To confirm this
Table 3. Hazard ratios of high-risk groups in three prognostic models.
Model Recurrence after 2 y Recurrence after 3 y Recurrence after 4 y
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
HIR signature (HIR or QT) 2.2 (1.3–3.8) 0.002 2.6 (1.3–5.4) 0.007 3.2 (1.2–8.5) 0.01
BROAD signature (high risk or low risk) 1.8 (1.0–3.2) 0.04 1.6 (0.7–3.7) 0.25 1.9 (0.6–5.9) 0.26
Combined signature (HIR and Broad high-risk
or QT and Broad low-risk)
3.4 (1.7–6.6) ,0.001 4.1 (1.5–10.5) 0.004 6.0 (1.7–10.7) 0.004
doi:10.1371/journal.pmed.1001770.t003
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Figure 5. STAT3 and NOTCH1 networks in the hepatic injury and regeneration signature. (A) Ingenuity transcription factor analysis
revealed that networks of genes considerably associated with STAT3 and NOTCH1 in the HIR signature. Upregulated and downregulated genes in the
HIR signature are indicated by red and green, respectively. Lines and arrows represent functional and physical interactions and the direction of
regulation as indicated from the literature. (B) Representative immunohistochemical staining of pSTAT3 (left panel) and STAT3 (right panel) in normal
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doi:10.1371/journal.pmed.1001770.g005
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prediction, we randomly selected 20 genes from the top ten
functional categories in Table S3 (two genes per category) (Table
S7) and constructed a prediction model with these 20 genes
(HIR20 model). Consistent with PAM, the miscalculation rate of
the HIR20 model for the HIR subgroup was 8%, and the
concordance of the HIR20 model with the original model was
significantly high (r=0.84 by Cramer V statistics, p,0.001) (Table
S8). Furthermore, the prognostic significance of the HIR20 model
was very similar to that of the original model (Figure 6A).
As an independent approach to finding the minimum number
of genes needed in the prediction model, we next carried out
multivariate logistic regression analysis. It identified four genes
(RALGDS, IER3, CEBPD, and SLC2A3) as independent
predictors of recurrence. We next tested whether the expression
data of these four genes would be sufficient to construct a reliable
prognostic model. Similar to the HIR20 model, the four-gene
prognostic model (HIR4) showed significant concordance with
original model (r=0.64 by Cramer V statistics, p,0.001) (Table
S9). The prognostic significance of the HIR4 model was also
highly similar to those of the HIR20 and original models
(Figure 6B). Taken together, our data strongly suggest that four
to 20 genes is sufficient to identify patients at high risk for late
recurrence.
We next assessed the reproducibility of the gene expression
measurements in our microarray study by carrying out qRT-PCR
experiments with RNAs from cohort 1. For 15 selected genes in
the HIR signature, expression from qRT-PCR experiments was
significantly correlated with the microarray results (Figure S9). In
particular, the correlations of 11 genes (BIRC3, GADD45B,
IL1RN, LDLR, CDKN1A, CCL20, DUSP5, BCL3, SERPINE1,
Figure 6. Concordance of HIR20 and HIR4 models with original HIR model. Patients were stratified by HIR20 model (A) or HIR4 model (B). All
patients (n= 396) are plotted in the left panel, those with early recurrence (#2 y) in the middle panel, and those with late recurrence (.2 y) in the
right panel. p-Values were obtained from the log-rank test. Vertical lines denote observations that were censored owing to loss to follow-up or on the
date of the last contact.
doi:10.1371/journal.pmed.1001770.g006
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PHLDA1, and C13ORF15) were extremely high (r.0.8; p,
0.001), suggesting that the expression data of most genes would be
highly reproducible. In addition, our data demonstrated high
concordance of four genes selected from multivariate logistic
regression analysis (Figure S10), further suggesting that a
prediction model can be developed with expression data from
simpler technology such as qRT-PCR.
Discussion
By analyzing gene expression data from human liver undergo-
ing liver injury and regeneration that mimics the wound-healing
process, and surrounding non-tumor liver tissues of patients with
HCC, we identified a signature that was significantly associated
with late recurrence (.2 y) after resection of the primary tumor.
The robustness of this signature was validated using three
independent cohorts with a total of 396 patients. Our results also
suggest that signaling pathways activated during HIR may play
important roles in de novo late recurrence of HCC, and are
potential explorable therapeutic targets for prevention of de novo
recurrence of HCC.
We further demonstrated that our previously developed tumor-
derived 65-gene risk score was strongest for predicting very early
recurrence (,1 y). Thus, genetic information from tumors may be
limited for predicting very early recurrence, but surrounding non-
tumor liver tissues may contain genetic information sufficient for
predicting late recurrence. These findings support a previously
developed notion that early recurrence might be largely due to
metastatic tumor regrowth of primary tumor while late recurrence
might be due to de novo tumor development from non-cancerous
lesions with predisposing risk [7,9].
A significant association of STAT3 activation with late
recurrence was suggested by the gene network analysis with the
HIR signature and later validated by immunohistostaining of the
surrounding liver tissues. Our findings are in good agreement with
previous studies demonstrating that STAT3 is necessary for both
liver regeneration following hepatic injury and hepatocarcinogen-
esis in mouse models [43,45]. The importance of STAT3 in de
novo recurrence is supported by the concordant high expression of
interleukin 6 (IL6) [46], a key upstream regulator of STAT3 in the
liver. An earlier study demonstrated that IL6 is accountable for a
higher incident rate of HCC in males than in females in a mouse
model [47], suggesting that higher IL6 expression and the
subsequent activation of STAT3 in surrounding liver ‘‘prime’’
events for tumor development. STAT3 can be also activated by
other cytokines such as IL22 and leptin [48,49], suggesting that
diverse pathways might be involved in activation of STAT3 and
increase susceptibility to de novo recurrence. The concomitant
activation of NOTCH1, and its potential cross-talk with STAT3 in
the HIR subgroup, is also intriguing because of the roles of both
proteins in stem cells and organ regeneration [50]. Previous studies
also support potential roles of other identified genes in the
prediction model. For example, higher expression of RALGDS in
HCC was previously reported, and silencing or inhibition of
RALGDS significantly reduced tumorigenesis in an animal model
[51]. Higher expression of CCL20 and SOCS3 was significantly
associated with poor prognosis after curative resection of HCC
tumors [52,53]. Our data provide evidence for the current notion
postulating that micrometastasis and de novo development are
accountable for early and late recurrence, respectively, and suggest
an update to the notion in recognition of the distinct molecular
mechanisms for each type of recurrence that are not shared.
A previous study identified a prognostic 186-gene expression
signature (the Broad signature) from surrounding non-tumor
liver tissues of HCC patients that was significantly associated
with late recurrence of HCC [20]. Only a few genes were shared
between the independently developed HIR and Broad signa-
tures of late recurrence, and the outcomes of the two prognostic
models showed only moderate concordance. Interestingly,
prognostication was substantially improved when the outcomes
of both prognostic models were integrated, suggesting that each
signature captures different biological characteristics that may
be equally important in late recurrence of HCC. However, we
cannot rule out the possibility that differences in the techno-
logical platforms account for there being only moderate
concordance between the two predictors: the Broad signature
was developed using a DASL (DNA annealing, selection, and
ligation) microarray platform and RNA from formalin-fixed
paraffin-embedded tissue, whereas the HIR signature was
developed using the Affymetrix microarray platform and RNA
from fresh-frozen tissues. In addition, there are substantial
differences in the patient populations of the two studies. Patients
in the Broad study were largely HCV-positive, while the patients
in our study were mostly HBV-positive. Therefore, differences
in etiologies between the two patient cohorts might be another
contributing factor accountable for the only moderate concor-
dance between the two models.
We also assessed the minimum number of genes required for a
reliable prediction model by several independent approaches.
First, PAM showed that ten to 20 genes would be sufficient to
construct a reliable predictor with an approximately 10%
miscalculation rate. Second, we found that a 20-gene predictor
(HIR20 model) worked as well as the full 233-gene HIR predictor
in identifying patients at high risk for late recurrence. Third,
multivariate logistic regression analysis revealed that as few as four
genes (HIR4 model) were sufficient to construct a reliable
predictor. Lastly, the robustness of microarray data was validated
by qRT-PCR experiments with the same RNAs used for
microarray experiments. Thus, our study also clearly demonstrat-
ed the feasibility of developing reliable predictors with a small
number of genes with the use of relatively simple technology such
as qRT-PCR.
Our study has some limitations. Tissues and clinical data were
retrospectively collected. Thus, our models need to be validated
in a prospective study, although we obtained the same results for
three independent patient cohorts. It is also important to point
out that prognostication of the HIR signature may be limited to
HBV-related HCC because the majority of the patients in our
study were HBV-positive. This could limit the generalizability of
our results. While the validation of the HIR signature in three
independent cohorts of patients with different ethnic and
environmental backgrounds enrolled in Korea and China
strongly supports the potential generalizability of our models,
it will be necessary to test our models in patients with different
etiological backgrounds such as HCV or obesity in a future
study.
In summary, we showed that two different genomic predictors
can identify patients at high risk for early and late HCC
recurrence. Because these recurrences are clinically different
entities with distinctive biological characteristics, separate rational
management or treatment recommendations can be developed.
For example, patients at high risk of late recurrence may benefit
from the use of JAK/STAT and NOTCH1 pathway inhibitors
after surgical resection [54,55]. Because current staging systems
and biomarkers are limited in their ability to assess patients’ risk of
recurrence and their potential benefit from adjuvant therapy, two
genomic predictors represent tools that could help refine treatment
decisions based on molecular profiles.
Genomic Predictors of HCC Recurrence
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Editors’ Summary
Background. Primary liver cancer—a tumor that starts
when a liver cell acquires genetic changes that allow it to
grow uncontrollably—is the second-leading cause of cancer-
related deaths worldwide, killing more than 600,000 people
annually. If hepatocellular cancer (HCC; the most common
type of liver cancer) is diagnosed in its early stages, it can be
treated by surgically removing part of the liver (resection), by
liver transplantation, or by local ablation, which uses an
electric current to destroy the cancer cells. Unfortunately, the
symptoms of HCC, which include weight loss, tiredness, and
jaundice (yellowing of the skin and eyes), are vague and
rarely appear until the cancer has spread throughout the
liver. Consequently, HCC is rarely diagnosed before the
cancer is advanced and untreatable, and has a poor
prognosis (likely outcome)—fewer than 5% of patients
survive for five or more years after diagnosis. The exact
cause of HCC is unclear, but chronic liver (hepatic) injury and
inflammation (caused, for example, by infection with
hepatitis B virus [HBV] or by alcohol abuse) promote tumor
development.
Why Was This Study Done? Even when it is diagnosed
early, HCC has a poor prognosis because it often recurs.
Patients treated for HCC can experience two distinct types of
tumor recurrence. Early recurrence, which usually happens
within the first two years after surgery, arises from the spread
of primary cancer cells into the surrounding liver that left
behind during surgery. Late recurrence, which typically
happens more than two years after surgery, involves the
development of completely new tumors and seems to be
the result of chronic liver damage. Because early and late
recurrence have different clinical courses, it would be useful
to be able to predict which patients are at high risk of which
type of recurrence. Given that injury, inflammation, and
regeneration seem to prime the liver for HCC development,
might the gene expression patterns associated with these
conditions serve as predictive markers for the identification
of patients at risk of late recurrence of HCC? Here, the
researchers develop a genomic predictor for the late
recurrence of HCC by examining gene expression patterns
in tissue samples from livers that were undergoing injury and
regeneration.
What Did the Researchers Do and Find? By comparing
gene expression data obtained from liver biopsies taken
before and after liver transplantation or resection and
recorded in the US National Center for Biotechnology
Information Gene Expression Omnibus database, the re-
searchers identified 233 genes whose expression in liver
differed before and after liver injury (the hepatic injury and
regeneration, or HIR, signature). Statistical analyses indicate
that the expression of the HIR signature in archived tissue
samples was significantly associated with late recurrence of
HCC in three independent groups of patients, but not with
early recurrence (a significant association between two
variables is one that is unlikely to have arisen by chance).
By contrast, a tumor-derived 65-gene signature previously
developed by the researchers was significantly associated
with early recurrence but not with late recurrence. Notably,
as few as four genes from the HIR signature were sufficient
to construct a reliable predictor for late recurrence of HCC.
Finally, the researchers report that many of the genes in the
HIR signature encode proteins involved in inflammation and
cell death, but that others encode proteins involved in
cellular growth and proliferation such as STAT3, a protein
with a well-known role in liver regeneration.
What Do These Findings Mean? These findings identify a
gene expression signature that was significantly associated
with late recurrence of HCC in three independent groups of
patients. Because most of these patients were infected with
HBV, the ability of the HIR signature to predict late
occurrence of HCC may be limited to HBV-related HCC and
may not be generalizable to HCC related to other causes.
Moreover, the predictive ability of the HIR signature needs to
be tested in a prospective study in which samples are taken
and analyzed at baseline and patients are followed to see
whether their HCC recurs; the current retrospective study
analyzed stored tissue samples. Importantly, however, the
HIR signature associated with late recurrence and the 65-
gene signature associated with early recurrence provide new
insights into the biological differences between late and
early recurrence of HCC at the molecular level. Knowing
about these differences may lead to new treatments for HCC
and may help clinicians choose the most appropriate
treatments for their patients.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001770.
N The US National Cancer Institute provides information
about all aspects of cancer, including detailed information
for patients and professionals about primary liver cancer
(in English and Spanish)
N The American Cancer Society also provides information
about liver cancer (including information on support
programs and services; available in several languages)
N The UK National Health Service Choices website provides
information about primary liver cancer (including a video
about coping with cancer)
N Cancer Research UK (a not-for-profit organization) also
provides detailed information about primary liver cancer
(including information about living with primary liver
cancer)
N MD Anderson Cancer Center provides information about
symptoms, diagnosis, treatment, and prevention of
primary liver cancer
N MedlinePlus provides links to further resources about liver
cancer (in English and Spanish)
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